Fig. 1.
Overview of the SafeStart study design. Pregnant women were mainly recruited through social media and allocated to either the intervention or control groups. Women in the intervention group were offered a tailored pharmacist consultation. All women received standard maternal care. The women responded to Q1 and Q2 between GW 3–13 and GW 14–26, respectively. The pharmacist consultations were performed from GW 4–14 for women in the intervention group. One woman received the intervention in GW 17. Self-reported data from the SafeStart questionnaires (Q1 and Q2) were linked to data from the Norwegian Prescription Database (NorPD) by using the women’s unique social security numbers. GW gestational week, Q1 baseline questionnaire, Q2 follow-up questionnaire. (Created with BioRender.com)
